alogliptin

FDA Drug Profile — Nesina

Drug Details

Generic Name
alogliptin
Brand Names
Nesina
Application Number
NDA022271
Sponsor
Takeda Ireland Ltd.
NDC Codes
9
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
ALOGLIPTIN BENZOATE

Indications and Usage

1 INDICATIONS AND USAGE Alogliptin and pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Alogliptin and pioglitazone tablets are a combination of alogliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Alogliptin and pioglitazone tablets are not recommended for use in patients with type 1 diabetes mellitus. ( 1 ) Limitations of Use Alogliptin and pioglitazone tablets are not recommended for use in patients with type 1 diabetes mellitus.